An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Benitec Biopharma Inc. (BNTC) will participate in the Citizens JMP Life Science Conference in New York on May 13-14, 2024, presenting its gene therapy-focused ddRNAi platform. The presentation by Jerel Banks, MD, PhD, Executive Chairman and CEO, will be webcasted live.
Benitec Biopharma Inc. (BNTC) parteciperà alla Conferenza JMP Life Science di Citizens a New York il 13-14 maggio 2024, dove presenterà la sua piattaforma focalizzata sulla terapia genica ddRNAi. La presentazione sarà tenuta da Jerel Banks, MD, PhD, Presidente esecutivo e CEO, e sarà trasmessa in diretta via web.
Benitec Biopharma Inc. (BNTC) participará en la Conferencia de Ciencias de la Vida de JMP de Citizens en Nueva York los días 13 y 14 de mayo de 2024, presentando su plataforma de terapia génica ddRNAi. La presentación, a cargo de Jerel Banks, MD, PhD, Presidente Ejecutivo y CEO, se transmitirá en vivo por internet.
Benitec Biopharma Inc. (BNTC)는 2024년 5월 13일부터 14일까지 뉴욕에서 열리는 Citizens JMP Life Science Conference에 참여하여 그들의 유전자 치료 중심 ddRNAi 플랫폼을 발표할 예정입니다. 이 발표는 제렐 뱅크스, MD, PhD, 집행 의장 겸 CEO에 의해 진행되며 생중계될 것입니다.
Benitec Biopharma Inc. (BNTC) participera à la Conférence JMP Life Science de Citizens à New York les 13 et 14 mai 2024, où elle présentera sa plateforme ddRNAi axée sur la thérapie génique. La présentation de Jerel Banks, MD, PhD, Président exécutif et CEO, sera diffusée en direct sur le web.
Benitec Biopharma Inc. (BNTC) wird am 13.-14. Mai 2024 an der Citizens JMP Life Science Konferenz in New York teilnehmen und seine auf Gentherapie basierende ddRNAi-Plattform präsentieren. Die Präsentation von Jerel Banks, MD, PhD, Executive Chairman und CEO, wird live im Web übertragen.
Positive
None.
Negative
None.
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.
Presentation Details: Date: May 13, 2024 Time: 11:00 am EDT Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer
The Benitec presentation will also be available via live webcast here.
Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.
AboutBenitecBiopharmaInc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
